These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 22922798

  • 1. IDH1 mutation of gliomas with long-term survival analysis.
    Myung JK, Cho HJ, Park CK, Kim SK, Phi JH, Park SH.
    Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R, Atli Eİ, Özdemir M, Çiftçi E, Aydin HE, Artan S, Arslantaş A.
    Gene; 2015 Jan 01; 554(1):81-6. PubMed ID: 25455102
    [Abstract] [Full Text] [Related]

  • 4. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, von Deimling A, Weller M, German Glioma Network.
    Clin Cancer Res; 2013 Sep 15; 19(18):5146-57. PubMed ID: 23918605
    [Abstract] [Full Text] [Related]

  • 5. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
    van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.
    Clin Cancer Res; 2010 Mar 01; 16(5):1597-604. PubMed ID: 20160062
    [Abstract] [Full Text] [Related]

  • 6. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T.
    Neuro Oncol; 2012 Jan 01; 14(1):109-16. PubMed ID: 22039037
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.
    Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.
    J Neurooncol; 2012 May 01; 107(3):617-31. PubMed ID: 22287028
    [Abstract] [Full Text] [Related]

  • 9. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C, Azevedo A, Esteves S, Marques AR, Martins C, Costa I, Mafra M, Bravo Marques JM, Roque L, Pojo M.
    BMC Cancer; 2019 Oct 17; 19(1):968. PubMed ID: 31623593
    [Abstract] [Full Text] [Related]

  • 10. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K, Wang YY, Ma J, Wang JF, Li SW, Jiang T, Dai JP.
    Asian Pac J Cancer Prev; 2014 Oct 17; 15(24):10893-8. PubMed ID: 25605197
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M.
    J Clin Oncol; 2009 Dec 01; 27(34):5743-50. PubMed ID: 19805672
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.
    Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D.
    J Neurooncol; 2011 Nov 01; 105(2):345-57. PubMed ID: 21643842
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP, Brodbelt AR, Haylock B, Zakaria R, Baborie A, Crooks D, Husband D, Shenoy A, Wong H, Jenkinson MD.
    Acta Neurochir (Wien); 2016 Oct 01; 158(10):1943-53. PubMed ID: 27526690
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.